Rapport Therapeutics, Inc. — Form 4
Filed August 26, 2026 · analyzed by the Insider Agent
4
▼ Likely negative
significance 54/100
What the filing says
Chief Development Officer Yeleswaram Krishnaswamy (RAPP) sold 50K shares (~$2.5M) on the open market (20% of holdings). Large sale — ~20% of holdings.
Why this rating
Large sale — ~20% of holdings.
See more from August 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.